Your browser doesn't support javascript.
loading
Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example.
Boehm, Markus; Hepworth, David; Loria, Paula M; Norquay, Lisa D; Filipski, Kevin J; Chin, Janice E; Cameron, Kimberly O; Brenner, Martin; Bonnette, Peter; Cabral, Shawn; Conn, Edward; Ebner, David C; Gautreau, Denise; Hadcock, John; Lee, Esther C Y; Mathiowetz, Alan M; Morin, Michelle; Rogers, Lucy; Smith, Aaron; VanVolkenburg, Maria; Carpino, Philip A.
Afiliación
  • Boehm M; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Hepworth D; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Loria PM; Department of Pharmacokinetics, Dynamics and Metabolism-New Chemical Entities, Primary Pharmacology Group, Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States.
  • Norquay LD; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Filipski KJ; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Chin JE; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Cameron KO; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Brenner M; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Bonnette P; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Cabral S; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Conn E; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Ebner DC; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Gautreau D; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Hadcock J; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Lee EC; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Mathiowetz AM; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Morin M; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Rogers L; Department of Pharmacokinetics, Dynamics and Metabolism-New Chemical Entities, Primary Pharmacology Group, Pfizer Worldwide Research and Development , Eastern Point Road, Groton, Connecticut 06340, United States.
  • Smith A; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • VanVolkenburg M; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
  • Carpino PA; Departments of Cardiovascular, Metabolic and Endocrine Diseases and Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
ACS Med Chem Lett ; 4(11): 1079-84, 2013 Nov 14.
Article en En | MEDLINE | ID: mdl-24900608
Orphan G protein-coupled receptors (oGPCRs) are a class of integral membrane proteins for which endogenous ligands or transmitters have not yet been discovered. Transgenic animal technologies have uncovered potential roles for many of these oGPCRs, providing new targets for the treatment of various diseases. Understanding signaling pathways of oGPCRs and validating these receptors as potential drug targets requires the identification of chemical probe compounds to be used in place of endogenous ligands to interrogate these receptors. A novel chemical probe identification platform was created in which GPCR-focused libraries were screened against sets of oGPCR targets, with a goal of discovering fit-for-purpose chemical probes for the more druggable members of the set. Application of the platform to a set of oGPCRs resulted in the discovery of the first reported small molecule agonists for GPR39, a receptor implicated in the regulation of insulin secretion and preservation of beta cells in the pancreas. Compound 1 stimulated intracellular calcium mobilization in recombinant and native cells in a GPR39-specific manner but did not potentiate glucose-stimulated insulin secretion in human islet preparations.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: ACS Med Chem Lett Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: ACS Med Chem Lett Año: 2013 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos